if a copied ReCell only needs an 510k approval then the costs are very moderate for any large pharma. But I don't know if it's only a 510k approval required.
PNV's BTM is a good example.
Patent extension, page-40
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.70 |
Change
-0.140(3.65%) |
Mkt cap ! $256.4M | |||
| Open | High | Low | Value | Volume |
| $3.77 | $3.77 | $3.63 | $163.4K | 44.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 565 | $3.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.72 | 1071 | 3 |
View Market Depth
| Last trade - 11.27am 18/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |